TAK1/MAP3K7 Recombinant Antibody

$Lane 1: Human Placenta; Probed with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Human Placenta; Probed with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 in N2A cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 in N2A cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Prostate tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Prostate tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse Stomach tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse Stomach tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Placenta tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Placenta tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Flow cytometric analysis of A431 cells with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

Applications

WB
FCM
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human
Mouse

Overview
Catalog #	bsm-54071R
Product Name	TAK1/MAP3K7 Recombinant Antibody
Applications	WB, FCM, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human, Mouse
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	C terminal Human MAP3K7
Clonality	Monoclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	6885
Swiss Prot	O43318
Synonyms	Mitogen-activated protein kinase kinase kinase 7, Transforming growth factor-beta-activated kinase 1, TGF-beta-activated kinase 1, MAP3K7, TAK1
Background	Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200